Only two of the 18 multinational pharmaceutical companies reported revenue declines in 2019

[pharmaceutical network industry trends] February is the annual report disclosure period At present, many multinational pharmaceutical enterprises have successively disclosed the 2019 financial statements Up to now, according to incomplete statistics in the industry, 18 multinational pharmaceutical enterprises have published annual report data, 16 of which have seen significant growth in performance and 2 have seen a decline in revenue In terms of revenue, Johnson & Johnson, Roche and Pfizer's three multinational pharmaceutical companies have revenue of more than 50 billion US dollars in 2019 Among them, according to the financial report of J & J in 2019, the annual net profit attributable to ordinary shareholders was US $15.119 billion, down 1.16% year on year, and the operating revenue was US $82.059 billion, up 0.59% year on year Roche's annual sales were CHF 61.46 billion (US $63.45 billion), up 9% year-on-year at a fixed exchange rate Among them, the pharmaceutical business reached CHF 48.51 billion, up 11% year-on-year; the diagnostic business reached CHF 12.95 billion, up 3% year-on-year Roche said that the growth of performance was driven by the strong driving force of four new drugs, namely Herceptin, avidin and rituximab, as well as ansanza and Pagett In addition, Roche's market in mainland China and Hong Kong rose 58% in the first half Pfizer's operating revenue in 2019 was US $51.75 billion, down 3.54% year-on-year, and net profit attributable to ordinary shareholders was US $16.273 billion, up 45.91% year-on-year, according to financial report data In the financial report, Pfizer chairman Dr Albert bourla said: "2020 will be an exciting year for Pfizer The Upjohn mylan transaction is expected to be completed in the middle of this year The new Pfizer company will be a small, science based company that focuses on innovation and will continue to distribute a large number of resources directly to shareholders mainly through dividends." Among the multinational pharmaceutical enterprises with significant performance growth, there are three with a year-on-year growth of more than 10% Among them, the annual revenue of Bristol Myers Squibb is US $26.145 billion, a year-on-year increase of 16%; the annual revenue of MSD is US $46.84 billion, a year-on-year increase of 10.75%; the annual revenue of GSK is US $33.754 billion, a year-on-year increase of 10% Among the 18 multinational pharmaceutical companies, only Pfizer and Amgen saw their revenue decline Among them, Pfizer's revenue in 2019 was US $51.75 billion, a year-on-year decrease of 3.54%; Amgen's revenue in 2019 was US $23.362 billion, a year-on-year decrease of 2% It is worth mentioning that in recent years, many multinational pharmaceutical companies have been impacted by the original research of drugs In order not to let some products affect their performance, many pharmaceutical companies have taken the way of splitting up, stripping off non core businesses, and making the main body of the company more focused on core businesses For example, MSD announced that it would spin off its women's health products, mature products and bio generic products, and set up a new independent listed company, which has not been named yet And MSD continues to hold innovative products, covering cancer treatment, vaccines, anesthesia, as well as its diabetes business and other important products GlaxoSmithKline also announced that in the next two years, the company will be divided into two entities: one is a biopharmaceutical company that focuses on the research and development of immune system related science using genes and new technologies, and the other is a health enterprise that focuses on consumer health The plan aims to support the new GlaxoSmithKline development by improving capital allocation, driving R & D restructuring, and adjusting and improving the capabilities and efficiency of global functional support departments, he said